UNSPSC 51334307: Chlorprothixene acetate

This classification denotes an antipsychotic agent C18H19ClNS.C2H3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K45X4JP9Q1, chemically known as 1-propanamine, 3-(2-chloro-9h-thioxanthen-9-ylidene)-n,n-dimethyl-, (z)-, acetate, but more generally known as chlorprothixene acetate, which bears US NIH Compound Identifier 24892861. European Medicines Agency schedules Chlorprothixene acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB35546.

Most nations, for tariff and trade purposes, schedule chlorprothixene acetate under HS 29349910 and SITC 51579. As of Q4 2014, CHLORPROTHIXENE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)[O-].C[NH+](C)CC/C=C\1/C2CCCCC2SC3C1CC(CC3)CL.

UNSPSC 51334307 Chlorprothixene acetate is a Commodity code that nominally covers a specific antipsychotic pharmaceutical compound, yet the recent state and local solicitations tagged under this code actually reflect broader pharmaceutical procurement across antipsychotics, opioid-reversal agents (naloxone), drug deactivation systems, and multi-source generic pharmaceuticals and over-the-counter products. State and local health agencies, cooperative purchasing consortia, and county health departments are the primary issuing bodies, with procurement driven by community health initiatives, pharmacy benefit management, and substance-abuse response programs. The work solicited ranges from direct procurement of finished pharmaceutical units through county health systems to cooperative statewide contracting for generic pharmaceutical supply chains serving multiple jurisdictions and administrative entities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 through its e-Procurement Portal. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. All three procurement vehicles emphasize compliance with federal manufacturing standards (cGMP, DSCSA, FDA requirements), wholesaler relationships, and electronic data interchange capability.